Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
暂无分享,去创建一个
R. Gascoyne | L. Sehn | J. Connors | K. Savage | T. Shenkier | R. Klasa | M. Chhanabhai | D. Villa | V. Mak | J. Hamm
[1] KyungMann Kim,et al. Contrasting treatment‐specific survival using double‐robust estimators , 2012 .
[2] R. Advani,et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Matthew Greenwood,et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] K. Savage. Therapies for peripheral T-cell lymphomas. , 2011, Hematology. American Society of Hematology. Education Program.
[5] B. Coiffier,et al. Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma , 2011 .
[6] Scott E. Smith,et al. Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL), , 2011 .
[7] S. Steinberg,et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.
[8] K. Savage,et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Reimer. Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas , 2010, Advances in hematology.
[10] P. Gaulard,et al. Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) , 2010 .
[11] V. Seshan,et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Weisenburger,et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Stefano A Pileri,et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.
[14] K. Ding,et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma , 2004, Cancer.
[15] D. Weisenburger,et al. Towards understanding the peripheral T-cell lymphomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] R. Gascoyne,et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] A. Hagenbeek,et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Neuberg,et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Armitage,et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.
[20] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .